Mediwound Ltd (MDWD) Expected to Post Earnings of -$0.16 Per Share

Wall Street analysts predict that Mediwound Ltd (NASDAQ:MDWD) will announce earnings per share of ($0.16) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Mediwound’s earnings. The highest EPS estimate is ($0.14) and the lowest is ($0.17). Mediwound posted earnings per share of ($0.09) in the same quarter last year, which indicates a negative year over year growth rate of 77.8%. The firm is expected to report its next earnings results on Tuesday, February 20th.

On average, analysts expect that Mediwound will report full year earnings of ($1.06) per share for the current financial year, with EPS estimates ranging from ($1.11) to ($1.01). For the next fiscal year, analysts expect that the firm will post earnings of ($0.69) per share, with EPS estimates ranging from ($1.16) to ($0.44). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Mediwound.

Mediwound (NASDAQ:MDWD) last posted its quarterly earnings data on Thursday, November 16th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.03. Mediwound had a negative net margin of 904.26% and a negative return on equity of 246.58%.

MDWD has been the subject of a number of research analyst reports. Zacks Investment Research cut shares of Mediwound from a “buy” rating to a “hold” rating in a research report on Tuesday, November 21st. Oppenheimer set a $10.00 price objective on shares of Mediwound and gave the stock a “buy” rating in a research report on Thursday, November 16th. ValuEngine upgraded shares of Mediwound from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 25th. Finally, SunTrust Banks set a $9.00 price objective on shares of Mediwound and gave the stock a “buy” rating in a research report on Thursday, November 16th. Two equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. Mediwound has a consensus rating of “Hold” and an average price target of $9.13.

Mediwound (NASDAQ:MDWD) opened at $4.05 on Wednesday. The firm has a market cap of $117.66, a price-to-earnings ratio of -4.13 and a beta of 0.01. Mediwound has a 12-month low of $3.55 and a 12-month high of $8.25.

Hedge funds and other institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN raised its position in shares of Mediwound by 23.5% in the second quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock valued at $447,000 after buying an additional 12,522 shares during the last quarter. Nationwide Fund Advisors acquired a new stake in shares of Mediwound in the third quarter valued at about $1,538,000. Alyeska Investment Group L.P. acquired a new stake in shares of Mediwound in the third quarter valued at about $2,140,000. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Mediwound by 5,084.4% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 754,434 shares of the biopharmaceutical company’s stock valued at $3,357,000 after buying an additional 739,882 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. raised its position in shares of Mediwound by 9.5% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,220,972 shares of the biopharmaceutical company’s stock valued at $11,882,000 after buying an additional 192,860 shares during the last quarter. Institutional investors and hedge funds own 29.46% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/07/mediwound-ltd-mdwd-expected-to-post-earnings-of-0-16-per-share.html.

About Mediwound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Get a free copy of the Zacks research report on Mediwound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply